CTOs on the Move

Octamer

www.octamer.com

 
Octamer is a Belvedere Tiburon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.octamer.com
  • 392 Cecilia Way
    Belvedere Tiburon, CA USA 94920
  • Phone: 415.381.1602

Executives

Name Title Contact Details

Similar Companies

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

Tanner Pharma

For over 18 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programmes, and source comparator drugs for clinical trials and bioanalysis. By partnering with Tanner Pharma, manufacturers are able to focus on their primary markets and strategies while ensuring that the services they need will follow a strictly controlled protocol of quality. Headquartered in the U.S. with offices in London, São Paulo and Mexico City, Tanner Pharma Group`s reach includes Europe, Asia, the Middle East, Australia, Canada and Latin America. We measure our value as a company based on the lives we help to improve. For all of us involved in the pharmaceutical supply chain - manufacturers, distributors, pharmacists, doctors, and others - it is ultimately the patient that matters most. Therefore, we start each day with a renewed commitment to ethically supply unlicensed medicines to markets where access continues being a challenge.

MBC Pharma (Main)

MBC Pharma (Main) is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Components

Dialysis and Vascular Access Products

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.